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Abstract:
Objective
This study was undertaken to evaluate the clinical spectrum of myasthenia
gravis in children and determine factors that help the clinician in his/her
diagnosis and management.
Materials & Methods
A retrospective review was performed on all pediatric patients suffering from
myasthenia gravis (M.G) admitted in the department of pediatric neurology
of the Mofid Hospital of the Shaheed Beheshti University, between 1994 and
2002.
Results
Of the thirty-two children with M.G. enrolled in our study, seven were suffering
from the congenital type while the remaining (25 cases) had the juvenile M.G.
Initial symptoms of congenital M.G were ptosis (7/7), limitation of eye movement
(2/7) and mild generalized weakness (6/7). Although the Tensilon test was
positive in 85% of congenital M.G cases, no myasthenia crisis or spontaneous
remission was observed in any of them. In children with juvenile M.G, the age
of presentation was 1.2 to 12.5 years, mean age 5.7+4.2 years (15 girls and
10 boys). The most common presenting symptoms in juvenile group were
ptosis in 96% and generalized weakness in 76%. Eight of them (32%) had had
at least one myasthenia crisis. EMG was diagnostic in 83% and one case the
tensilon test was positive in 84%. One patient had hyperthyroidism and had
already been diagnosed with hypothyroidism; two of them were epileptics.
Eight patients underwent thymectomy microscopically; in specimens examined,
five (62%) showed thymic follicular hyperplasia while in remaining three results
were normal. One patient (12.5%) recovered completely after thymectomy
with no need for medication during the follow up. Four patients (50%) showed
relative improvement and in three cases (37%) improvement was negligible.
Conclusion
The results showed a female to male ratio of 1.5/1 which was correlated to
adult M.G. The most common presenting symptoms consisted of ophtalmoplegia,
with bilateral ptosis being the most significant. Although this study revealed
that  thymectomy lacks any remarkable prognostic influence, all patients had
thymectomy after two years of disease onset. Some reports have indicated
positive results if surgery was performed within two years of onset of disease.
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Introduction
Willis first described myasthenia gravis (MG) in 1672
(1) and its onset in childhood was recognized by Erb in
1879(2). Three broad forms of myasthenia in infants and
children are are now  which consist of known ;
autoimmune MG, also known as juvenile myasthenia
gravis (JMG), congenital myasthenia gravis (CMG), also
known as genetic MG; and transient neonatal MG (3,4).
Juvenile myasthenia gravis is an autoimmune disease,
in which at least two autoimmune antibody mediated
processes underlie autoimmune MG, targeting the
acetylcholine receptor (AChR) in the majority and muscle-
specific kinase (MuSK) in the minority of patients (5).
Congenital myasthenia gravis, a combination of multiple
inherited disorders of neuromuscular transmission and
neonatal MG, is a transient disease due to placental
transfer of antibodies from a myasthenic mother to her
baby during pregnancy (6,7). Three to seven percent of
MG cases begin before the age of 10 years and 16-30%,
before the age of 20 years (8).
Considering the marked differences between the clinical
course and management of CMG and JMG, the differential
diagnosis between the two is very important. Study and
diagnosis of the defect causing CMG requires
sophisticated techniques which are not available in most
centers(6). We studied a series of childhood MG cases
to determine the distinguishing clinical features of CMG
and JMG, and to assess their responses to
anticholinesterase drugs, steroids and thymectomy.
Patients & Methods
We reviewed the chart of 32 patients with the diagnosis
of myasthenia gravis that had been referred to our center
between 1994 and 2002. Data was obtained using records
of Mofid hospital and telephone interviews. Diagnosis
of MG was based on the association of clinical signs of
fluctuating weakness of voluntary muscles with
fatigability and at least one of the following criteria;
unequivocal improvement after I.V edrophonium (positive
tensilon test) injection, electrophysiological signs of
abnormal neuromuscular transmission such as a
decrement more than 10% in compound muscle action
potential on low-rate supramaximal repetitive nerve
stimulation and ruling out of other causes of muscle
weakness. Serum anticholinesterase antibodies were
checked only for 5 patients because this test was not
available till recently. Severity of disease was graded
according to the Osserman and Genkins scale (9).
Patients were classified as CMG if they had one of the
following: criteria (i) onset before 1 year of age , (ii)
onset before 5 years of age  and MG history in a sibling
or relative and no response to corticosteroid. Other
patients were categorized as J.MG.
Parental consanguinity was not included among the
criteria since consanguineous marriage is very common
in Iran.
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Results
Thirty-two patients experienced myasthenic weakness
which seven of them (2 girls and 5 boys) were affected
by CMS; the onset of disease was at birth in 3 patients,
and in the remaining 4 it was within the first year. Family
history was positive in 3 patients (42.8%), tensilon test
was positive in 6 of them (85.7%), EMG with repetitive
stimulation was positive in 4 patients (57%). Three patients
had only ophthalmic involvement and 3 of them had
ptosis associated with mild generalized weakness and
one patient had generalized weakness, ptosis and bulbar
involvement. None of the patients with CMS developed
any acute crisis. One patient was lost in follow up, whereas
others were followed for between 3 months to 9 years
with a mean follow up of 3.017±3.26 years. Of 6 patients
followed, 5 patients showed relatively good response to
mestinone; for one patient with ophthalmic myasthenia
who had no response to mestinone, steroids and IVIG
were tried, but there was no response.
In 25 patients with JMG ( 15 girls, 10 boys (F/M=1.5/1),
the onset age was 1.2- 12.5 years; No patients had a family
history of muscle weakness. Six patients (24%) complained
of ocular myasthenia (Osserman's-grade I) the other 19
cases had generalized MG; Seven cases (28%) presented
with mild disease (grade 2A), 4 (16%) with moderately
severe (grade 2B) and very severe MG with respiratory
crises (grades 3 and 4) was seen in eight patients (32%).
Three patients had 4 crises, while one patient had two.
One patient (4%) had hyperthyroidism, one (4%)
hypothyroidism and two patients (8%) had epilepsy. Two
patients had positive family histories of hypothyroidism
in first degree relatives.
Anticholinesterase antibodies were checked in 5 patients,
of which in 3 (60%) they were positive. Tensilon test was
positive in 21 out of 25 patients (84%). Electrromyogram
with repetitive stimulation test was done in 18 patients
being positive in 15 (83%). In nineteen patient chests x-
ray or CT scans were done; four patients (21%) showed
an increased thymus shadow.
Anticholinesterase therapy was administered to all patients,
and of these, for ten steroids was also added. For seven
patients with myasthenic crises, IVIG was administered,
and plasma exchange also used for one patient with a
crisis. Follow up duration ranged from between 0.2 to 7
years (mean 3.03±3.2 years).
Thymectomy was performed in seven patients, who did
not have a good response to anticholinesterase and steroids.
None of them underwent early thymectomy. Histologic
examinations showed four of them (57%) had hyperplastic
thymuses and three did not. One patient (14%) had
complete recovery after thymectomy, needing no
medication; two patients (28%) showed relative
improvement after thymectomy, while four (57%) showed
none.
Five patients (20%) had remission several months, four
with generalize MG and one with ocular myasthenia.
Three patients treated only with anticholinesterase and
one patient with steroid and anticholinesterase and one
patient had remission several months after thymectomy.
Moderate improvement was observed in 15 patients (60%);
five patients (20%) did not have good response, and three
patients improved after thymectomy (Table 2).
Discussion
The prevalence of autoimmune MG with onset in the first
decade is lower than in the general population, with the
exception of Chinese and Japanese patients in whom a
high incidence of ocular MG is reported (7).
There is no documented information about the prevalence
of myasthenia gravis in childhood and adult at our center;
during the past 10 years only 25 patients with juvenile
myasthenia, 7 patients with congenital myasthenia were
recorded at our referral hospital. (This hospital is the most
important referral center for pediatric neurology disease
in Iran).
Although often difficult, it is important to distinguish the
congenital and juvenile forms of childhood myasthenia,
because of the differences in their clinical courses and
treatment. Symptoms appearing in infancy indicate CMG
(6). MG if present in first-degree relatives, strongly
suggests hereditary MG syndromes, but the incidence of
autoimmune MG in relatives of JMG patients is also
higher than in the normal population (4%) (8). Acetylcholin
receptor antibody may be absent in up to 44% of JMG
cases, limiting the value of this test in the diagnosis of
JMG (1). Detailed electrophysiological and morphological
studies of the muscle indicate various defects causing
CMG; however there are few centers that can perform
such evaluations. In our center, diagnosis of congenital
MG is based on onset of disease and positive family
history.
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We studied these MG patients for the clinical features,
family history, associated autoimmune disease, and
response  to  immunosuppress ive  t rea tment .
In our study, congenital MG was significantly more
common in males (5/2=M/F), results that differed from
those of the Anal and et al study; however the JMG ratio
however was similar to theirs, i.e. slightly more common
in female (9, 10). This result is in contrast with the strong
female prevalence in late onset patients (4.2/1) and can
confirm the minimal influence of sex hormones on the
disease pathogenesis at this age (11). In our study, 28%
of JMG patients had only ocular myasthenia, 32% had
severe disease with respiratory involvement showing JMS
is more benign than late-onset MG, results similar to the
Andrews study, and different to the studies of  Evoli and
Anlar, that show 42.1% with respiratory involvement
(9,11,2). Positive family histories of myasthenia reported
in our study were 42.8%, as compared to 70% in the Evoli
and et al study (11).
The tensilon test and electrodiagnostic study is also
beneficial in diagnosis of prepubertal JMG. In our study
84% of JMG, 59% of CMG had positive tensilon test,
83% of JMG, 85.7% of CMG cases had positive EMG
findings, compatible with results of other studies (12). In
literature on JMG, although the seropositive rate varies
(13,1); acetylcholin receptor antibodies was checked only
in five patients in our study, being positive in 3, similar
to other studies and less than that in the adult onset MG
(9,1,2).
Various diseases of autoimmune and non-autoimmune
origin have been described in association of JMG in
childhood (1, 14, 15). The most common autoimmune
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disease associated with JMG in our study was thyroid
disease; also epilepsy was more common in JMG in
comparison with the general population, but none of
CMG cases had any other associated disease.
In our study as in other studies, thymoma was not seen
in patient pathology reports (9,10,11). Some authors
report good results after surgery in prepubertal children
(16,17,18), while others describe a lower remission rate
in younger rather than in older patients (2,19).
In our study also no beneficial result was seen after
thymectomy; in 57% there was no response to
thymectomy, which might be due to the delay in decision
for thymectomy; optimum results are obtained if
thymectomy is done within 2 years of onset.
Conclusion
Myasthenia gravis is a relatively rare disease in our
center; clinical presentation, response to treatment and
prognosis are similar to those described elsewhere,
whereas response to thymectomy in our patients is
relatively poor because of delays in operation. Hence
early thymectomy for myasthenic patient with no response
to steroid and anticholinesterase drugs is recommended.
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